Consolidated Statements of Changes in Shareholders’ Equity - USD ($) |
Class A
Ordinary Shares
|
Class B
Ordinary Shares
|
Additional Paid-in Capital |
Retained Earnings |
Accumulated Other Comprehensive Income (Loss) |
Non-controlling interest |
Total |
|---|---|---|---|---|---|---|---|
| Balance at Mar. 31, 2024 | $ 37,017 | $ 28,903,950 | $ 11,713,813 | $ (123,875) | $ 40,530,905 | ||
| Balance (in Shares) at Mar. 31, 2024 | 37,015,807 | ||||||
| Share-based compensation | $ 29 | 72,194 | 72,223 | ||||
| Share-based compensation (in Shares) | 28,668 | ||||||
| Net loss | (5,969,348) | (5,969,348) | |||||
| Foreign currency translation adjustment | 251,524 | 251,524 | |||||
| Balance at Mar. 31, 2025 | $ 37,046 | 28,976,144 | 5,744,465 | 127,649 | 34,885,304 | ||
| Balance (in Shares) at Mar. 31, 2025 | 37,044,475 | ||||||
| Retirement of Class A ordinary shares | $ (10,000) | (10,000) | |||||
| Retirement of Class A ordinary shares (in Shares) | (10,000,000) | ||||||
| Issuance of Class B ordinary shares | $ 10,000 | 10,000 | |||||
| Issuance of Class B ordinary shares (in Shares) | 10,000,000 | ||||||
| Share-based compensation | $ 50 | 60,144 | 60,194 | ||||
| Share-based compensation (in Shares) | 49,941 | ||||||
| Capital injection from non-controlling shareholders | 305,736 | 305,736 | |||||
| Net loss | (1,170,823) | (4,716) | (1,175,539) | ||||
| Foreign currency translation adjustment | 169,039 | 410 | 169,449 | ||||
| Balance at Mar. 31, 2026 | $ 27,096 | $ 10,000 | $ 29,036,288 | $ 4,573,642 | $ 296,688 | $ 301,430 | $ 34,245,144 |
| Balance (in Shares) at Mar. 31, 2026 | 27,094,416 | 10,000,000 |
| X | ||||||||||
- Definition Amount of capital injection from non-controlling shareholders. No definition available.
|
| X | ||||||||||
- Definition Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares issued which are neither cancelled nor held in the treasury. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|